AZmed vs Infervision (2026)
Two non United States imaging vendors reading different films for different departments. AZmed is trauma first, detecting fractures, effusions and dislocations on plain radiographs, aimed at the emergency queue where a missed finding most reliably becomes a complaint, with a clearance covering adult and pediatric use that is reported to be unique in that segment. Infervision spans lung nodule detection and chest interpretation across modalities with United States operations alongside its origin market. They barely overlap clinically, so the choice is which reading burden you are attacking. Both fit the pattern this index records for non Western imaging vendors: thorough regulatory dossiers, thin commercial assurance, so ask for attestations directly.
- It is trauma first, detecting fractures, joint effusions and dislocations, which is the highest volume plain film reading in any emergency department.
- The fracture clearance covers both adult and pediatric use, reported to be unique in that segment, with a strong clearance study design.
- Distribution runs directly and through several imaging platform partners, so adoption does not depend on one integration route.
- Its suite spans lung nodule detection and chest interpretation with United States operations alongside its origin market.
- Coverage extends across modalities rather than radiography alone, so one vendor reaches more of the imaging estate.
- For a buyer wanting an established American support relationship from a non Western vendor, that presence matters.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AZmed and Infervision are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AZmed | Infervision |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2018 | 2015 |
| Headquarters | Paris, France | Beijing, China |
| Website | azmed.co | global.infervision.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
AZmed
-
EHR / interoperability
AZmed's FDA cleared AZtrauma and AZchest X-ray apps are now available on the Rapid Enterprise Platform, which RapidAI says more than 2,500 hospitals use.
Source -
Clinical evidence
CHU de Reims, which has used AZmed's fracture detection on all patients since 2021, published an independent evaluation in Pediatric Radiology.
Source -
Regulatory / FDA
AZmed received its sixth FDA clearance, for AZchest to detect and localize pneumothorax and pleural effusion on chest radiographs.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Paris based imaging AI company whose Rayvolve suite reads plain radiographs: AZtrauma detects fractures, dislocations and joint effusions, AZchest covers chest findings including pneumothorax, pleural effusion and lung nodules, and AZmeasure and AZboneage add measurements and bone age. A second suite, Rayscan, detects lung nodules on CT.
Source: AI Health Index, August 2026
Beijing based imaging AI company whose InferRead line detects findings on CT and radiographs (lung nodules on chest CT, chest abnormalities on radiographs, coronary stenosis on CTA, hemorrhage on head CT, chest fractures and pneumonia), alongside the InferOperate suite of 3D reconstructions for thoracic, liver and urologic surgical planning, InferCare for patient follow up and RECIST tumor assessment, and the InferScholar research and InferMatrix application platforms.
Source: AI Health Index, August 2026
Questions buyers ask
How do AZmed and Infervision work with the EHR?
For AZmed, the company reports use at more than 2,500 sites in more than 55 countries and 15.4 million X-rays analyzed in the last twelve months, and its clearances rested on studies at named US institutions, University Hospitals in Cleveland and SimonMed Imaging. It has also been distributed through third party cloud radiology workflow platforms, including RADIN.
With Infervision, the InferRead Lung CT.AI 510(k) summary (K240554) lists DICOM image input and reporting of results, with detection marks delivered as an overlay on the original CT. The product is reported in use at SimonMed, a US outpatient imaging provider, and in tuberculosis screening programs. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are AZmed and Infervision priced and sold?
In AZmed's case, the software has been sold both directly and through cloud radiology platforms. The company's scale figures, more than 2,500 sites in more than 55 countries, describe use, not price.
For Infervision, the company is reported to offer several pricing options rather than a single model, and its tuberculosis screening deployments were procured through international agencies by public tender, where the price is disclosed to the purchaser rather than published. The products are sold directly and through public procurement, but what drives the cost is not stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do AZmed and Infervision handle patient data?
With AZmed, the home page describes SOC 2, GDPR and HIPAA compliant infrastructure. The privacy policy, approved in December 2025, covers the website, billing, prospecting and recruitment, with retention periods for those records only; it does not address images or outputs processed by Rayvolve or Rayscan.
In Infervision's case, the InferRead Lung CT.AI 510(k) summary (K240554) says the software can run in the healthcare facility or on a cloud platform, and that cybersecurity and vulnerability analyses found it conforms to the cybersecurity requirements, a general assurance about the product. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
What evidence is published for AZmed and Infervision?
For AZmed, a 2026 multicenter analysis by Cohen and colleagues covers 258,373 X-rays from 100 centers in 26 countries.
With Infervision, the company's research page lists more than 330 peer reviewed publications and conference abstracts, and the home page names none of them for a product sold. Deployment is reported at scale, including a US partnership with SimonMed and tuberculosis screening programs procured through international agencies in Eastern Europe and Central Asia and in Zimbabwe; the home page reports coverage of more than 30 countries. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Compare these per body region and per finding rather than on aggregate claims, since a trauma product and a chest product share almost no performance surface. Both are non United States origin vendors and the index records the same pattern for that group: regulatory effort follows market access while commercial assurance documentation is thinner, so ask for attestations and business associate terms explicitly. Prevalence in your own population determines the false positive burden more than published sensitivity, and neither publishes performance stratified that way.